India's FMRAI union is calling for a mass strike by pharma sales reps in November as protests over working practices gather strength.

Just weeks after Aralez’s purchase of Zontivity, the drugmaker nabbed an FDA approval for its twice-delayed cardiovascular drug Yosprala. The new med's…

It’s been awhile since Novartis’ rare disease med Ilaris picked up a label-expansion boost, but now the Swiss drugmaker has three of them to show for its…

Just months after signing on with the Walter Reed Army Institute of Research to develop a Zika vaccine, Sanofi Pasteur won a $43 million vote of confidence…

Poor sales trajectory, check. Scale-back in marketing effort, check. What’s next for Valeant’s Addyi and its maker, Sprout? An impairment charge, if you ask…

With brand-new hiked-up sales forecasts for its newest meds, Bayer is hoping for a home run from prostate cancer-fighter Xofigo--and it's counting on a…

Merck’s Keytruda could become a national tourist attraction in China, with a special approval for imports to the resort island of Hainan.

Sanofi and Regeneron’s next wannabe blockbuster is officially in regulators’ hands--but with the candidate tapped for a speedy review process, it may not stay…